- Technical notes
- Selection guides
Cellartis hiPS-cardiomyocytes citation list
Takara Bio has over 15 years of experience deriving cardiomyocytes from human pluripotent stem cells under the Cellartis brand. The cardiomyocytes comprise a mixture of atrial, nodal, and ventricular phenotypes, express expected cardiac biomarkers, and exhibit an electrophysiological profile similar to adult primary cardiomyocytes. These features make the cells ideal for drug discovery applications, disease modeling, phenotypic screening, safety pharmacology, and cardiotoxicity testing. Read below for a citation list of studies in which Cellartis stem cell-derived cardiomyocytes were used in peer-reviewed basic, translational, preclinical, and biomedical research.
Andersson, H. et al. Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. J. Biotechnol. 150, 175–81 (2010).
Améen, C. et al. Human embryonic stem cells: current technologies and emerging industrial applications. Crit. Rev. Oncol. Hematol. 65, 54–80 (2008).
Asp, J. et al. Cardiomyocyte clusters derived from human embryonic stem cells share similarities with human heart tissue. J. Mol. Cell Biol. 2, 276–83 (2010).
Björquist, P. & Jeppsson, A. Cell transplantation for myocardial regeneration: hype or reality? Scand. Cardiovasc. J. 38, 259–64 (2004).
Jonsson, M. K. et al. Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes. Expert Opin. Drug Discov. 4, 357–72 (2009).
Jonsson, M. K. B. et al. Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4, 189–200 (2010).
Jonsson, M. K. B. et al. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J. Mol. Cell. Cardiol. 52, 998–1008 (2012).
Mandenius, C.-F. et al. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. J. Appl. Toxicol. 31, 191–205 (2011).
Meyer, T., Sartipy, P., Blind, F., Leisgen, C. & Guenther, E. New cell models and assays in cardiac safety profiling. Expert Opin. Drug Metab. Toxicol. 3, 507–17 (2007).
Nalos, L. et al. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. Br. J. Pharmacol. 165, 467–78 (2012).
Norström, A. et al. Molecular and pharmacological properties of human embryonic stem cell-derived cardiomyocytes. Exp. Biol. Med. (Maywood). 231, 1753–62 (2006).
Sartipy, P. & Björquist, P. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment. Stem Cells 29, 744–8 (2011).
Steel, D., Hyllner, J. & Sartipy, P. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery. Curr. Opin. Drug Discov. Devel. 12, 133–40 (2009).
Synnergren, J., Améen, C., Lindahl, A., Olsson, B. & Sartipy, P. Expression of microRNAs and their target mRNAs in human stem cell-derived cardiomyocyte clusters and in heart tissue. Physiol. Genomics 43, 581–94 (2011).
Synnergren, J., Améen, C., Jansson, A. & Sartipy, P. Global transcriptional profiling reveals similarities and differences between human stem cell-derived cardiomyocyte clusters and heart tissue. Physiol. Genomics 44, 245–58 (2012).
Synnergren, J. et al. Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells 26, 1831–40 (2008).
Vidarsson, H., Hyllner, J. & Sartipy, P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev. 6, 108–20 (2010).
Learn how to use our cardiomyocytes with the following high-throughput platforms:
Perform real-time kinetic assessment of Ca2+ flux and cardiac beating using Cellartis cardiomyocytes with this protocol for the FLIPR Tetra High-Throughput Cellular Screening System.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.